Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine
about
Recent developments and future prospects in the treatment of visceral leishmaniasisModulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory MoleculesPossibilities and challenges for developing a successful vaccine for leishmaniasisStrategies to overcome antileishmanial drugs unresponsivenessThe neglected tropical diseases of India and South Asia: review of their prevalence, distribution, and control or eliminationBiomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.Immune regulation during chronic visceral leishmaniasis.Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs.Vaccines to prevent leishmaniasis.IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisTherapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Use of defined TLR ligands as adjuvants within human vaccines.A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.Whole genome sequencing of live attenuated Leishmania donovani parasites reveals novel biomarkers of attenuation and enables product characterization.Chemotherapeutics of visceral leishmaniasis: present and future developments.Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated Leishmania Parasite Vaccines.
P2860
Q26740563-241C855A-6DFF-4987-A829-A01F009FB699Q26744635-1F43C7EB-3479-4C58-B31F-6E5EE5F83841Q26749758-7213FD7B-C8B2-4586-862B-4FBB56C5C9C4Q26849297-9452C4B2-B88B-48B9-AA27-D1F569857B93Q27006539-2C5436F1-6C2F-451D-88DE-65CFE5DD5FA7Q33659753-84AE6CE5-55CB-437B-B5C9-E3A19107807FQ33881718-42274D15-4068-42DD-B2E4-569E755CDD35Q34314496-BA7C661E-4B48-4A9D-809C-601AD9573B78Q34511559-CCC53EE5-9339-474B-841E-FC13A99030A3Q34792941-DBCA5D7A-B3DB-4CED-8ADF-70EAD14C8A68Q35138682-73C2DF38-55BD-40B0-B9B7-529A0CB027A5Q35741989-BDD34194-C586-4BD9-93CB-674459772D90Q37825528-7E8C644D-1CA8-47BD-BA86-1CB99047A25DQ40244179-390F1903-7ED4-422F-B658-A17335B4CDBDQ40541534-C6AF79D9-B806-4CD4-A10E-5EF1AEED7AEBQ40957138-57CBE594-F971-4B95-AC6C-4B0BA94F2CB4Q46713325-3AE0AE45-6935-4CF6-80BE-72E3C9ED1C45Q51372327-190D429D-7596-4E83-8157-A1D0AEB0907F
P2860
Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@ast
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@en
type
label
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@ast
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@en
prefLabel
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@ast
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@en
P2860
P50
P1476
Evaluation of ex vivo human im ...... visceral leishmaniasis vaccine
@en
P2093
Kamlesh Gidwani
P2860
P304
P356
10.4269/AJTMH.2010.09-0341
P407
P577
2010-05-01T00:00:00Z